title: Dyslipidaemia. Assessing the efficacy and safety of evolocumab and alirocumab.
authors.forename: Karina
authors.initials: K
authors.lastname: Huynh
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000097:blood*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000188:drug therapy*; D008297:Male
chemical_list: D000911:Antibodies, Monoclonal; D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
references.citation: N Engl J Med. 2015 Apr 16;372(16):1489-99
references.pmid: 25773378
references.citation: N Engl J Med. 2015 Apr 16;372(16):1500-9
references.pmid: 25773607